Atezolizumab and motixafortide, cobimetinib or simlukafusp alfa in pretreated advanced pancreatic cancer: phase I/IIb MORPHEUS-PDAC umbrella study
The overall safety of atezolizumab combinations was manageable and consistent with each agent's known safety profile. This novel trial design enabled rapid evaluations of 3 atezolizumab combinations; all had limited efficacy as 2 L or 3 L treatment for metastatic PDAC. New treatments are needed to improve outcomes in previously treated PDAC.
Authors
- B. George
- Gulam A. Manji (ORCID: https://orcid.org/0000-0001-9817-2414)
- Angela Alistar (ORCID: https://orcid.org/0009-0009-0473-7513)
- J. Siveke
- Edward Cha (ORCID: https://orcid.org/0000-0001-8172-0656)
- Roby Thomas (ORCID: https://orcid.org/0000-0003-4828-4586)
- Jill Lacy
- Mariano Ponz-Sarvise
- V. Chung
- T. Macarulla
- Yun Xu
- Kyu-Pyo Kim
- Eileen M O’Reilly
- Janet Lau
- Charles D Lopez
- Do-Youn Oh
Institutions
- Hebron University (PS)
- City Of Hope National Medical Center (US)
- Memorial Sloan Kettering Cancer Center (US)
- Oregon Health & Science University (US)
- German Cancer Research Center (DE)
- Medical College of Wisconsin (US)
- Columbia University Irving Medical Center (US)
- Yale Cancer Center (US)
- Seoul National University Hospital (KR)
- Yale University (US)
- University of Ulsan (KR)
- West Cancer Center (US)
- Roche (China) (CN)
- Kaiser Permanente South San Francisco Medical Center (US)
- University of Pittsburgh Medical Center (US)
- Clinica Universidad de Navarra (ES)
- Atlantic Health System (US)
- Universidad de Navarra (ES)
Publication Details
- Journal
- The Oncologist
- Published
- 2026-02-24
- DOI
- https://doi.org/10.1093/oncolo/oyag023
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- F. Hoffmann-La Roche